Abbott Laboratories Stock News

When selecting dividend stocks to buy, investors are faced with a variety of choices. However, we like healthcare stocks for many reasons, particularly given inherent recession resilience and long-ter

The global Treatment for Hormonal Imbalance market size is projected to reach US$ 27.3 Billion by 2027, at a CAGR of 8.6% during 2021-2027. Hormonal imbalance, including menopause, are the key variables driving the market for chemical substitution treatment. The

The Cancer Genome Projects'' goal is to classify sequence variants and changes critical in the growth of human cancers. The project involves the systematic screening of coding genes and flanking splice junctions of all genes in the human genome for

The advantages of advanced drug delivery systems over outmoded systems are the aptitude to deliver a drug more selectively to an exact site easier, more accurate, less frequent treating reduced erraticism in systemic drug attentions absorption that is more consistent

The Continuous Glucose Monitoring (CGM) Devices Market covers the present scenario (with the base year being 2021) and the growth prospects of global Continuous Glucose Monitoring (CGM) Devices market for 20212028. The report discusses the key drivers influencing market growth,

New York State Teachers Retirement System trimmed its position in shares of Abbott Laboratories (NYSE:ABT) by 2.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,178,055 shares of the healthcare product makers stock after selling 58,380 shares during the period. New []

Osborne Partners Capital Management LLC raised its holdings in shares of Abbott Laboratories (NYSE:ABT) by 2.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 103,723 shares of the healthcare product maker’s stock after purchasing an additional 2,418 shares during the period. […]

The portfolio generated $1,067 in dividends during the month, an improvement over August. YTD, I've received $12,700. I closed out my positions in REM, DIS, MLPA, and SPYD.

Ferguson Wellman Capital Management Inc. lifted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 2.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 47,419 shares of the healthcare product makers stock after buying an additional 1,210 shares during the []

Abbott Laboratories (NYSE:ABT) EVP Andrea F. Wainer sold 4,500 shares of the stock in a transaction that occurred on Monday, December 6th. The shares were sold at an average price of $132.50, for a total transaction of $596,250.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available []

Spire Wealth Management grew its holdings in shares of Abbott Laboratories (NYSE:ABT) by 5.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 140,376 shares of the healthcare product makers stock after purchasing an additional 6,711 shares during the quarter. Spire Wealth []

Abbott (ABT) closed at $132.37 in the latest trading session, marking a -0.04% move from the prior day.

Plimoth Trust Co. LLC lifted its holdings in Abbott Laboratories (NYSE:ABT) by 3.5% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 23,655 shares of the healthcare product makers stock after acquiring an additional 805 shares during the quarter. Plimoth Trust Co. LLCs holdings in []

Abbott's Covid test kits which have enabled the company to rapidly overcome mid-2020 revenue lows are now essential tools in limiting infection rates throughout the world.